Evidence map›Paper›PMID 41869894›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Reinforcing Calcium Overload via Inflammation-Mediated Targeting to Amplify Pyroptosis and Antitumor Immunity.

Yingying Liu, Yang Liu, Qin Fan, Jinqiao Zhang, Kexin Wen, Boyu Yuan, Xianzhou Cai, Ziliang Dong, Lianhui Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yingying LiuDepartment of Clinical Pharmacy, Shandong Key Laboratory of Digital Diagnosis and Treatment of Thoracic Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, P. R. China.
Yang LiuSchool of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, Singapore, Singapore.
Qin FanState Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjing, Jiangsu, P. R. China.
Jinqiao ZhangScience and Technology Innovation Center, Shandong First Medical University& Shandong Academy of Medical Sciences, Jinan, Shandong, P. R. China.
Kexin WenScience and Technology Innovation Center, Shandong First Medical University& Shandong Academy of Medical Sciences, Jinan, Shandong, P. R. China.
Boyu YuanScience and Technology Innovation Center, Shandong First Medical University& Shandong Academy of Medical Sciences, Jinan, Shandong, P. R. China.
Xianzhou CaiScience and Technology Innovation Center, Shandong First Medical University& Shandong Academy of Medical Sciences, Jinan, Shandong, P. R. China.
Ziliang DongDepartment of Clinical Pharmacy, Shandong Key Laboratory of Digital Diagnosis and Treatment of Thoracic Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, P. R. China.
Lianhui WangState Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjing, Jiangsu, P. R. China.ORCID https://orcid.org/0000-0001-9030-9172

Funding

National Natural Science Foundation of China 22307057National Natural Science Foundation of China 52302350Natural Science Foundation of Jiangsu Province BK20220401Qingfeng Program of Shandong First Medical UniversityShandong Provincial Natural Science Foundation ZR2024QC370Shandong Provincial Taishan Scholars Program tsqn202312237
6 · The paper itself

Abstract

Tumor-associated inflammation presents a promising therapeutic target, yet it remains insufficiently exploited in current nanomedicine approaches. While inflammation-driven strategies, such as inducing pyroptosis, have the potential to enhance tumor immunity, their limited induction efficiency and poor tumor targeting still pose significant challenges. Herein, we engineer a neutrophil membrane-camouflaged nanoplatform (RC@NMVs) that exploits tumor inflammation to drive reinforcing calcium dyshomeostasis and pyroptotic amplification. This biomimetic system comprises calcium phosphate (CaP) nanoparticles co-loaded with the calcium channel blocker, ruthenium red. Upon internalization by tumor cells, the CaP core dissolves within lysosomes, releasing Ca

Indexed as

CalciumInflammationNeoplasmsPyroptosisAnimalsCalcium PhosphatesHumansMiceNanoparticlesCalciumcalcium phosphateCalcium Phosphatescalcium stressimmune activationinflammation amplifyingpyroptosistumor treatment

Identifiers

PMID41869894
PMCPMC13587957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.